Loading
A phase 1/2 trial of Gemcitabine, Paclitaxel / nab-paclitaxel, Cetuximab in non-small-cell lung cancer and small-cell lung cancer, run by Bristol-Myers Squibb, now recruiting.
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT07223047 by Bristol-Myers Squibb, with 252 participants planned, started 2025-11-25 and due to reach its primary completion in 2028-10-13. Interventions recorded: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab. Conditions listed: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.
Shares Cetuximab, Gemcitabine, Small-cell lung cancer, Pembrolizumab.
Shares Cetuximab, Paclitaxel / nab-paclitaxel, Gemcitabine, Pancreatic ductal adenocarcinoma.
Shares Bristol Myers Squibb, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Bristol Myers Squibb, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Bristol Myers Squibb, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Cetuximab, Colorectal cancer, Non-small-cell lung cancer.
Shares Bristol Myers Squibb, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.